ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 222 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q2 2022. The put-call ratio across all filers is 1.13 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $27 | +285.7% | 748 | +392.1% | 0.02% | +300.0% |
Q2 2023 | $7 | +40.0% | 152 | +16.9% | 0.01% | +25.0% |
Q1 2023 | $5 | -58.3% | 130 | -49.6% | 0.00% | -20.0% |
Q4 2022 | $12 | -99.8% | 258 | +52.7% | 0.01% | -16.7% |
Q3 2022 | $7,000 | 0.0% | 169 | +36.3% | 0.01% | 0.0% |
Q2 2022 | $7,000 | -22.2% | 124 | -0.8% | 0.01% | 0.0% |
Q1 2022 | $9,000 | +50.0% | 125 | +76.1% | 0.01% | -25.0% |
Q4 2021 | $6,000 | – | 71 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
EcoR1 Capital, LLC | 519,119 | $40,605,000 | 3.00% |
First Light Asset Management, LLC | 236,958 | $18,535,000 | 2.16% |
SECTOR GAMMA AS | 108,734 | $8,505,000 | 1.76% |
Rock Springs Capital Management LP | 646,841 | $50,596,000 | 1.39% |
Atika Capital Management LLC | 79,000 | $6,180,000 | 0.80% |
Capital Impact Advisors, LLC | 30,582 | $2,392,000 | 0.80% |
FEDERATED HERMES, INC. | 4,080,359 | $319,166,000 | 0.79% |
Rhenman & Partners Asset Management AB | 61,500 | $4,811,000 | 0.52% |
Ikarian Capital, LLC | 73,500 | $5,749,000 | 0.46% |
Capital International, Inc./CA/ | 477,858 | $37,378,000 | 0.46% |